STAT Plus: TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin
TG Therapeutics (TGTX) on Tuesday delayed yet again the readout from its most important blood cancer clinical trial. And like the previous delay of study results disclosed in September 2018, the biotech’s CEO is papering over the very real risk of failure.
Final results from a Phase 3 clinical trial called UNITY-CLL had been expected to read out in the first quarter, based on the company’s own guidance. On Tuesday, CEO Mike Weiss copped to a problem: The required number of tumor progression events needed to analyze the study haven’t occurred as expected.
